ProQR Therapeutics (PRQR) Debt to Equity (2021 - 2025)

ProQR Therapeutics (PRQR) has disclosed Debt to Equity for 5 consecutive years, with $0.1 as the latest value for Q4 2025.

  • Quarterly Debt to Equity rose 90.72% to $0.1 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.1 through Dec 2025, up 90.72% year-over-year, with the annual reading at $0.1 for FY2025, 90.72% up from the prior year.
  • Debt to Equity hit $0.1 in Q4 2025 for ProQR Therapeutics, up from $0.05 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.39 in Q4 2021 to a low of $0.05 in Q4 2024.
  • Historically, Debt to Equity has averaged $0.15 across 5 years, with a median of $0.1 in 2022.
  • Biggest five-year swings in Debt to Equity: tumbled 73.72% in 2022 and later soared 90.72% in 2025.
  • Year by year, Debt to Equity stood at $0.39 in 2021, then crashed by 73.72% to $0.1 in 2022, then rose by 2.12% to $0.1 in 2023, then tumbled by 50.11% to $0.05 in 2024, then skyrocketed by 90.72% to $0.1 in 2025.
  • Business Quant data shows Debt to Equity for PRQR at $0.1 in Q4 2025, $0.05 in Q4 2024, and $0.1 in Q4 2023.